Loteprednol Etabonate API

Loteprednol etabonate is a corticosteroid used primarily in ophthalmology for:

• Postoperative inflammation (e.g., after cataract surgery)

• Allergic conjunctivitis

• Uveitis (anterior segment)

• Dry eye disease (in combination with other agents)

Brand Examples:

• Lotemax® (0.5% ophthalmic suspension)

• Alrex® (0.2% for allergic conjunctivitis)

3. Mechanism of Action

• Soft Corticosteroid: Metabolized to inactive byproducts, reducing systemic side effects.

• Anti-inflammatory: Inhibits phospholipase A₂ → reduces prostaglandins/leukotrienes.

• Low Intraocular Pressure Risk: Compared to dexamethasone/prednisolone.

4. Literature Review

Key Clinical Studies

1. Postoperative Inflammation (Cataract Surgery)

   • Pavesio et al. (2010): Lotemax® showed efficacy equal to prednisolone acetate with fewer side effects.
     DOI: 10.1016/j.jcrs.2009.10.040
     

2. Allergic Conjunctivitis

   • Dell et al. (2008): Alrex® 0.2% significantly reduced itching/redness.
     DOI: 10.1016/j.ophtha.2007.06.038
     

3. Safety Profile

   • Fong et al. (2015): Minimal impact on IOP vs. other steroids.
     DOI: 10.2147/OPTH.S80085
     

Synthesis & API Patents

• US Patent 4,996,335 (Bausch + Lomb): Original synthesis.

• WO 2017/100456: Improved polymorphic forms for stability.

5. Pharmacokinetics

• Ocular Absorption: Rapidly hydrolyzed to active metabolite (Δ¹-cortienic acid etabonate).

• Half-life: ~2–3 hours (local action, minimal systemic exposure).